Indivior | Evaluate

November 28, 2022

C4X gets another small deal from big pharma

Indivior fights off generic challenges but the threat of litigation remains

Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.

April 10, 2019

Indivior’s problem isn’t generics, and it might ensnare Reckitt, too

February 20, 2019

Indivior salvages what it can with generic launch

November 21, 2018

Suboxone decision puts pressure on Indivior follow-up products

June 27, 2018

More pain for Pain, but Cara saves face for now

April 30, 2018

Interview – Addex looks up from abyss

With fresh investors Addex's time in the investor wilderness might be coming to an end.

January 26, 2018

Snippet roundup: High times for cannabis companies and Indivior

November 17, 2017

Snippet roundup: Three approvals and more pricing headaches

November 02, 2017

Indivior gets new injection of life

October 27, 2017

Upcoming events – Adcom for Indivior and Haven 3 data for Roche

Load More